Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TACR1 | P25103 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | FDFT1 | P37268 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3749425 | 0.79 | SYK (0.40) | LMNATACR1MAPTKMT2AKCNH2 | |
| SCHEMBL3758208 | 0.77 | ABCB1 (0.39) | MEN1KMT2A | |
| SCHEMBL3761734 | 0.77 | KCNA3 (0.39) | LMNAMEN1KMT2AKCNH2SMN1; SMN2 | |
| SCHEMBL27708332 | 0.73 | CYP19A1 (0.48) | HTT | |
| SCHEMBL11336572 | 0.70 | L3MBTL1 (0.48) | LMNAMEN1MAPTKMT2ANPSR1 | |
| SCHEMBL9278852 | 0.69 | HTR7 (0.40) | — | |
| SCHEMBL9232425 | 0.69 | HTR7 (0.40) | — | |
| SCHEMBL12243769 | 0.69 | AOC3 (0.39) | LMNAHTT | |
| SCHEMBL1045709 | 0.68 | HTT (0.38) | LMNAHTT | |
| SCHEMBL22649183 | 0.68 | HTR7 (0.39) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-8202513-B2 | Aryl potassium channel blockers and uses thereof | BIONOMICS LIMITED (AU) | 2012-06-19 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2010-11-25 | — | — | US | disclosed |
| WO-2009043117-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | BIONOMICS LIMITED (AU) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100297077-A1 | NOVEL ARYL POTASSIUM CHANNEL BLOCKERS AND USES THEREOF | KCNA3, KCNB1, KCNH3 | LMNA 2758/4885TACR1 850/4885MEN1 4032/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.